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OAR dose tolerance. No relationship was identified between 
the % difference of OAR volumes and D2cc OAR % variations. 
 
Conclusion: Patients treated with 45Gy in 25 fractions EBRT 
+ 21Gy in 3 fractions VBT are at greater risk of breaching OAR 
dose tolerances when using a single planning scan for all 
treatments. There is no significant relationship between the 
% difference of bladder, rectum, sigmoid and small bowel 
volumes and % dose difference. The OAR dose variation 
between each scan is most likely due to the unpredictable 
day to day movement of the structure and cannot be 
replicated by standardised organ filling procedures. 
Departmental protocols have been amended to CT plan this 
subgroup of patients before each treatment fraction to take 
into account position of structure at that time. Use of a 
multichannel applicator could also help minimise the dose to 
these structures. 
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Purpose or Objective: A report of late rectal and bladder 
toxicitiy outcomes of a computed tomography(CT)-based 
image guided brachytherapy(IGBT) technique for treatment 
of cervical cancer.  
 
Material and Methods: Between 2008-2014, 95 women with 
International Federation of Gynecology and Obstetrics stage 
IB to IVA cervical carcinoma treated with definitive 
concurrent cisplatin based chemotherapy and external beam 
radiation therapy (EBRT) 50.4Gy in 28 fractions followed by 
3-4 fractions of high-dose-rate (HDR) IGBT was 
retrospectively reviewed. At each implantation, all patients 
had a urinary catheter insitu and received bowel enema 
before undergoing planning CT-simulation. A high-risk clinical 
target volume (HRCTV) encompassing any visible tumor and 
the entire cervix, rectum and bladder was contoured on the 
simulation CT according to Radiation Therapy Oncology Group 
Gynaecology Contouring Atlas. Prescription dose range of 5.5-
7Gy was prescribed to the HRCTV. Doses to Point A, ICRU 
rectal and bladder points were recorded. Toxicities were 
recorded using NCI-CTCAE version 3. 
 
Results: The median follow-up time was 29 months. The 
mean Point A dose was 6Gy (4.6-7.6Gy). The ICRU rectum and 
bladder points were 4.69Gy (2.5-5.7Gy) and 4.23Gy (1.95-
7.2Gy) respectively. 22 patients(23%) and Grade 2 proctitis 
and 10 patients(11%) had Grade 3 proctitis. 4 patients (4%) 
had Grade 2 cystits and 2 patients(2%) had Grade 3 cystitis. 
No patients had ≥ Grade 4 toxicity.  
 
Conclusion: Despite bladder and bowel preparation protocol, 
late rectal toxicity was significant in a high proportion of 
patients. Implementation of an interstitial IGBT using the 
EMBRACE protocol might help to limit these late rectal 
toxicities. 
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Purpose or Objective: To analyze the preliminary results of 
a new daily high-dose-rate brachytherapy (BT) schedule in 
vaginal-cuff relapse (VCR) and toxicity in postoperative 
endometrial carcinoma (EC). 
 
Material and Methods: From September 2011 to December 
2014, 102 patients (p) were treated with HDRBT in FIGO 
stages: IA-30p, IB-39p, II-8p, IIIA-4p, IIIB-1p, IIIC1-8p, IIIC2-
5p, IIIC3-1p, IVB-6p. Pathology: 79/102 endometrioid 
adenocarcinoma and 23/102 other types. Radiotherapy: 
Group 1: 74p/102p 1 BT fraction of 7Gy after external beam 
irradiation (mean 45Gy, range 44.0-50.4); Group 2: 28p/102p 
BT alone by 3 daily fractions of 6Gy. Chemotherapy: 20/102 
patients. Toxicity evaluation: RTOG scores for bladder and 
rectum and the objective criteria of LENT-SOMA for vagina. 
Statistics: Chi-square and Fisher exact tests. 
 
Results: Mean age (years): Group 1: 65.4 (40-88), Group 2: 
66.7 (39-90). Mean follow-up (months): Group 1: 24.48 (8.04-
52.56); Group 2: 26.88 (8.76-54.48). VCR: No relapses with 
the present mean follow-up. Toxicity: Group 1 - early 
problems (all G1-2) in rectum (5.5%), bladder (6.8%) and 
vagina (14.9%). Late toxicities: rectum 2.7% (all G1), bladder 
0% and vagina 27% (G1-G2). Group 2 -early toxicity: bladder 
10.7% (all G1), vagina 28.1% (all G1-G2), rectum 0%; late 
toxicity was only found in vagina in 17.8% (G1-2). No 
significant differences were found in toxicities between the 
two groups. 
 
Conclusion: The present brachytherapy schedule consisting 
in 1 fraction/7Gy after external beam irradiation and 3 
fractions/6Gy administered daily seem a safe regime in terms 
of local control and toxicity for postoperative EC. These 
results seem similar to those found in our Hospital in 2 
previous series with low dose per fraction and an increased 
number of fractions. Grant: AECC Foundation 
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Purpose or Objective: To develop a reliable method of 
determining the radiation dose to the vaginal mucosa in the 
treatment of cervical cancer. 
 
Material and Methods: Forty six cervical cancer patients 
were treated with EBRT and HDR brachytherapy therapy from 
July 2010 – Dec 2013. They received 45Gy in 25 fractions of 
EBRT to the entire pelvis followed by 3 HDR brachytherapy 
fractions using a tandem and ring applicator with a HRCTV 
D90 of 80-85Gy. A volume to represent the vaginal mucosa 
was obtained by using a non-uniform expansion of the 5mm 
ring applicator cap; this was expanded by 5.0 mm in all 
directions except the sup/inf which was expanded by 7.0 
mm. In addition, a rectal vaginal (RV) point dose was 
determined using a point 5.0 mm posterior to the 
intersection of the superior-posterior junction of the build up 
cap (figure 1 sagittal view). Total doses were calculated for 
vaginal volumes of 5.0cc (D5 v), 2.0cc (D2 v), and the RV 
point. In addition, the slope was calculated for the vaginal 
mucosa between D5 v and D2 v. Pearson correlation 
coefficients (with p values = 0.01) were assessed to identify 
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correlations between the slope, D5 v, D2 v, HRCTV D90, 
HRCTV volume, and the RV point. 
 
Results: Total doses from 3 fractions for the D5 v median 
48.7Gy (range 31.4 - 76.6Gy), D2 v median 64.0Gy (range: 
43.2 - 112Gy) and RV median dose 16.3Gy (range: 11.6 – 
25.3Gy) The RV point exhibited a weak correlation with D2 v 
(r=0.56; p=0.0001) and D5 v (r = 0.55; p=0.0001) respectively. 
A moderate correlation was observed between the HRCTV 
volume and the D2 v (r = 0.69; p=0.0001), the HRCTV volume 
and D5 v (r = 0.73; p=0.0001) and a weak correlation with the 
HRCTV volume and the RV Point (r=0.57; p=0.0001). The 
slope correlated with D2 v (r= -0.96; p=0.0001) and D5 v (r=-
0.87; p=0.0001) and a weak correlation with the RV point (r=-
0.52; p=0.0002). No correlation was found between the 
HRCTV D90 and the D2v (r=-0.20; p=0.1826), the D5v (r=-
0.24; p=0.1082), or the RV Point (r=0.02; p=0.8431). 
 
Conclusion: The expansion volume of the ring applicator cap 
can provide a suitable surrogate for determining the vaginal 
mucosa dose, as this part of the vagina is in close proximity 
to the ring and tandem contributing to the volume of vaginal 
mucosa receiving the highest vaginal dose. The RV point does 
not correlate with the D2v and D5v and therefore can not to 
be use as a suitable surrogate point for the dose to the 
vaginal mucosa. Additional work is currently ongoing to 
correlate the D2v and D5v with clinically measured vaginal 
morbidity. 
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Purpose or Objective: In order to evaluate the usefulness of 
high-dose-rate image-guided interstitial brachytherapy (HDR-
ISBT) for recurrent uterine cervical adenocarcinoma, we 
analyzed our clinical experience. 
 
Material and Methods: We investigated 28 patients treated 
with HDR-ISBT at National Hospital Organization Osaka 
National Hospital between May 2003 and December 2010. All 
patients received radical surgery and 7 patients also received 
post-operative radiotherapy as previous treatments. 
Histologic finding was adenocarcinoma and squamous cell 
carcinoma for 11 and 17 patients. In 11 adenocarcinoma 
patients, 6 patients had endometrioid adenocarcinoma and 
the other 5 patients had mucinous adenocarcinoma. The 
median tumor size was 23 mm (range; 5-79 mm). In 21 
patients who had no irradiation history, 9 patients were 
treated with HDR-ISBT alone and the other 12 patients were 
treated with HDR-ISBT plus external beam radiotherapy 
(EBRT). Forty-eight to 54 Gy in 8 to 9 fractions were 
delivered as monotherapy and 30 to 33 Gy in 5 to 6 fractions 
as combination of EBRT. In 7 patients who had irradiation 
history, slight lower doses (42 to 48 Gy in 7 to 8 fractions) 
were selected. We implanted 7–15 (median, 12) applicators 
under transrectal ultrasonography guidance. We used free-
hand implantation with ambulatory technique for later 25 
patients. Magnetic resonance imaging (MRI)-assisted image-
based treatment planning was performed for later 17 
patients. Clinical target volumes (CTV) were the gloss tumor 
volume with or without 10 mm of vaginal margin for patients 
with or without non-irradiation history. 
 
Results: The median follow-up time was 43 months (range; 4-
115 months). The median D90(CTV)s were 120%prescribed 
dose (PD), 122%PD and 118%PD for patients who had 
endometrioid adenocarcinoma, mucinous adenocarcinoma 
and squamous cell carcinoma. The 3-year local control and 
overall survival rates were 72% and 73% for adenocarcinoma. 
The 3-year local control and overall survival rates were 88% 
and 77% for squamous cell carcinoma. No significant 
difference was observed. The 3-year local control rates were 
both 67% for endometrioid adenocarcinoma and mucinous 
adenocarcinoma. Grade 3-4 late complications occurred by 
HDR-ISBT in 5 patients (18%). 
 
Conclusion: Our treatment result of image-based HDR-ISBT 
showed that slight inferior result was observed in cervical 
adenocarcinoma although there was no significant difference. 
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Purpose or Objective: Brachytherapy is one the most 
important components in the treatment of cervical cancer. 
Recently 3D planning for brachytherapy has been used which 
could be done both by CT and MRI imaging based. We 
compared the high risk clinical target volumes contoured on 
CT and MRI and dose distribution in the target volumes and 
organs at risk. 
 
Material and Methods: Twenty three patients with IIA-IIIB 
stage cervical cancer were planned for HDR brachytherapy 
with ring-tandem applicators. Treatment consisted of four 7 
Gy fractions by two insertion procedures. On MRI and CT sets 
we contoured HR CTV and organs at risk on 42 plans: for 19 
patients two plans and for four patients only one. Medical 
physicists received task to make planning on CT and MRI 
images independently at the same day before irradiation. 
The mean HR CTV volume, dose received by at least 90% of 
the volume (D90) and the dose to 2 cc for the organs at risk 
were evaluated. 
 
Results: The mean volume of HR CTV was 77.5 cc on CT 
based contours and 60.3 cc on MRI imaging. This difference in 
HR CTV volume reflected on the dose to organs at risk – 
physicists have to increase it to achieve prescribed dose in 
target volume. Thus, while assessing mean D2cc for rectum, 
bladder and sigmoid we find out that it was lower in case of 
MRI based planning compare to CT based planning – 66.2 Gy 
and 70.3 Gy, 85.1 Gy and 89.6 Gy, 62.3 Gy and 66.7 Gy 
respectively. Mean D90 also was significantly higher in MRI 
compared to CT imaging plans – 94,2% versus 79,4% of 
prescribed dose. 
 
Conclusion: In spite that superiority of MRI compared to CT 
imaging based contouring and planning for HR CTV dose 
distribution has been already showed in previous studies we 
found that it also allows indirectly significantly decrease the 
dose to organs at risk during HDR brachytherapy for cervical 
cancer. 
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Purpose or Objective: To retrospectively assess treatment 
outcome of image guided brachytherapy (IGBT) with or 
without hybrid technique for cervical cancer using 
VariSourceTM titanium ring applicator with ‘Siriraj Ring Cap’ 
extension (as figure 1). In case of narrow vaginal opening, 
hybrid brachytherapy technique could be performed using 
this applicator with extension. 
Figure 1: VariSourceTM titanium ring applicator with ‘Siriraj 
Ring Cap’ extension 
